Bayer Files for Approval of gadoquatrane in the U.S.
FDA submission seeks approval for investigational gadolinium-based contrast agent (GBCA) gadoquatrane for contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) and other body regions for adults and pediatric patients including term neonates
Submitted dose corresponds to a 60 percent reduction in gadolinium compared to macrocyclic GBCAs dosed at 0.1 mmol gadolinium per kilogram of body weight
Not intended for media outside of the US
WHIPPANY, N.J., June 17, 2025--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for contrast-enhanced magnetic resonance imaging of the CNS and other body regions in adults and pediatric patients including term neonates. The submitted dose is 0.04 mmol gadolinium per kilogram body weight. If approved, gadoquatrane would become the lowest dose macrocyclic GBCA available in the U.S., corresponding to a 60 percent reduction compared to macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight.
The submission of gadoquatrane to the US FDA is based on positive data from the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane in adult and pediatric patients globally. The first results from the Phase III QUANTI CNS study were presented at the European Congress of Radiology (ECR) in February of this year and further results are planned to be presented at upcoming scientific meetings.
Nearly 40 million MRI scans are performed each year in the United States. "There is a rising need for medical imaging, among others driven by the increasing incidence of chronic diseases such as cancer and cardiovascular diseases," said Dr. Konstanze Diefenbach, Head of Radiology Research & Development, Bayer. "As a leader in radiology, we are committed to advancing innovation in this field, including options to reduce the gadolinium dose. Patients can benefit from a dose reduction, especially patients with chronic conditions who require multiple contrast-enhanced MRI examinations during their lifetime. This is in line with guidance from health authorities and guidelines from scientific bodies which recommend using the lowest dose required to obtain the needed clinical information."
Bayer recently announced the submission of gadoquatrane to the Ministry of Health, Labour, and Welfare (MHLW) in Japan, marking the first application for marketing authorization for the investigational contrast agent. Further regulatory applications to health authorities worldwide are planned for the coming months.
About the Phase III development program QUANTIThe pivotal QUANTI clinical development program investigated gadoquatrane at a dose of 0.04 mmol Gd/kg body weight, which represents a 60 percent lower gadolinium dose compared to macrocyclic contrast agents dosed at 0.1 mmol Gd/kg body weight. QUANTI consisted of two large multinational, randomized, prospective double-blind, crossover Phase III studies – QUANTI CNS (Central Nervous System) and QUANTI OBR (Other Body Regions) – as well as the QUANTI Pediatric study. In total, 808 patients in 15 countries participated in the program. The QUANTI study results show that gadoquatrane met the primary and secondary efficacy endpoints of the studies assessing visualization parameters and lesion detection.
Results of QUANTI Pediatric demonstrated that the pharmacokinetic behavior of gadoquatrane in children is similar to that in adults. The observed safety profile in adults as well as pediatric patients from birth to < 18 years of age in the QUANTI studies was generally consistent with previous data on gadoquatrane and other macrocyclic GBCAs. No new safety signals were observed.
About gadoquatraneGadoquatrane is Bayer's investigational extracellular macrocyclic contrast agent in clinical development for contrast enhancement in MRI. This low dose gadolinium-based contrast agent features a distinct tetrameric structure with high stability and high relaxivity.
About MRIWith an estimated 65 million procedures performed annually worldwide, contrast-enhanced MRI plays a key role in the healthcare continuum. MRI is a non-invasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues. This supports physicians in answering critical medical questions related to the detection and monitoring of diseases.
About Radiology at BayerBuilding on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer's comprehensive offerings also include informatics solutions and a medical imaging platform with digital and artificial intelligence (AI) powered applications. In 2024, Bayer's radiology products generated €2.1 billion in sales. Bayer continues to advance research and innovation in medical imaging, including the integration of AI.
About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.
Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616347143/en/
Contacts
Contact for media inquiries: Victoria Vigener, phone +49 151 23438911 Email: victoria.vigener@bayer.com
Contact for US media inquiries: Jennifer May, phone, 412-656-8192 Email: jennifer.may@bayer.com
Find more information at www.bayer.com.
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Intel to outsource marketing to Accenture and AI, resulting in more layoffs
When you buy through links on our articles, Future and its syndication partners may earn a commission. Employees at Intel's marketing division were informed that many of their roles will be handed over to Accenture, which will use AI to handle tasks traditionally done by Intel staff, reports OregonLive. The decision is part of a company-wide restructuring plan that includes job cuts, automation, and streamlining of execution. The marketing division has been one of Intel's key strengths since the company began communicating directly with end users with the launch of its "Intel Inside" campaign in 1991. However, it looks like the company will drastically cut its human-driven marketing efforts going forward, as it plans to lay off many of its marketing employees, believing that Accenture's AI will do a better job connecting Intel with customers. The number of positions affected was not disclosed, but Intel confirmed changes will significantly alter team structures, with only 'lean' teams remaining. Workers will be told by July 11 whether they will remain with the company. Among other things, the aim of the restructuring is to free up internal teams to focus on strategic, creative, and high-value projects, rather than routine functions. Therefore, Intel intends to use Accenture's AI in various aspects of marketing, including information processing, task automation, and personalized communications. Intel has acknowledged the shift to Accenture and explained that this will not only cut costs but will modernize its capabilities and strengthen its brand. How exactly the usage of AI instead of real people can reinforce the brand hasn't been explained yet. "As we announced earlier this year, we are taking steps to become a leaner, faster and more efficient company," a statement by Intel published by OregonLive reads. "As part of this, we are focused on modernizing our digital capabilities to serve our customers better and strengthen our brand. Accenture is a longtime partner and trusted leader in these areas and we look forward to expanding our work together." In messages to staff published by OregonLive, Intel indicated that part of the restructuring may involve existing employees training Accenture contractors by explaining how Intel's operations work. This knowledge transfer would occur during the transitional phase of the outsourcing plan, although it is unclear how long this phase will take. Follow Tom's Hardware on Google News to get our up-to-date news, analysis, and reviews in your feeds. Make sure to click the Follow button.
Bloomberg
33 minutes ago
- Bloomberg
Malaysia Says US Agrees to Finalize Trade Talks Before Deadline
Malaysia and the US have agreed to finalize trade negotiations before the tariff reprieve expires, the Malaysia's Ministry of Investment, Trade and Industry said. 'Both Malaysia and the US representatives expressed their intent to finalize the negotiations before the expiry of the 90-day pause on tariff implementation and agreed to intensify efforts to reach an agreement that would be mutually acceptable by key stakeholders from both countries,' according to a statement from the ministry on Sunday.
Yahoo
38 minutes ago
- Yahoo
2 world-class growth shares to consider buying during a stock market crash
It's always a smart idea to have a shopping list of shares at hand. This is what I had in April when the proverbial hit the fan, saving me valuable time deciding which stocks to buy when many suddenly went on sale. Two on my list were Shopify and Nvidia, and I took my chance when things quickly went south. Those positions are currently up 40% and 51% respectively since early April. Here are two shares that look overvalued, but which I think investors should consider putting on a shopping list for the next bear market or crash. The first is Axon Enterprise (NASDAQ: AXON). As well as owning the Taser brand, the company sells body-cams, dash-cams, and various software products to law enforcement customers. It's also innovating in drones, VR training, and powerful artificial intelligence (AI)-powered tools. Last year, revenue jumped 33% to $2.1bn, up from $681m in 2020. Over $1bn of that is now annual recurring revenue, while total future contracted bookings rose to $10.1bn. The company continues to scale up very impressively. This rapid progress is reflected in the share price, which has vaulted 700% in three years. The key risk now then is valuation, with the shares trading at 27 times sales. If Axon's growth underwhelms, the stock could sell off heavily. But I think this is definitely one to consider picking up during any such sell-off. The enterprise growth opportunity's very large. Take body-cams, for example. In an attempt to reduce attacks on staff, Walmart's piloting black-and-yellow body-cams in some stores (Axon's signature colours). Management points out that Walmart has 2.1m retail workers, far in excess of the 900,000 cops in the US. What about airlines? Cabin crew are no strangers to abusive behaviour. Cameras can provide evidence, reduce false claims, and deter aggression. They would integrate with Axon's cloud-based evidence system, adding to the recurring revenue. Meanwhile, the company's sitting on a library of video data that's roughly 40 times larger than that belonging to Netflix (NASDAQ: NFLX). Axon's using this vast data trove to train AI models and power a growing suite of tools, embedding it ever deeper into customers' daily workflows. Looking ahead, the international opportunity in Europe, Latin America and Asia remains largely untapped. Returning to Netflix, I think the global streaming leader is worthy of consideration. But perhaps not right now around $1,220. This price puts the stock at 13 times sales and 49 times forward earnings. Again, this stretched valuation leaves very little margin for error, particularly if subscriber growth unexpectantly slows. Long term though, I'm bullish on Netflix. The firm possesses an incredible brand and streaming still has plenty of room to grow globally. It also offers fantastic value for money. At £12.99, my Netflix subscription's probably one of the last discretionary things I would cut. The new ad-supported tier is just £5.99 a month — less than the price of a pint in London nowadays! I think Netflix can keep increasing prices for years without losing too many subscribers. The firm has set a goal of reaching a $1trn market-cap by 2030, up from $520bn today. I think that's achievable, especially if cutting-edge generative AI helps it make content for less money. The post 2 world-class growth shares to consider buying during a stock market crash appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Ben McPoland has positions in Axon Enterprise, Nvidia, and Shopify. The Motley Fool UK has recommended Axon Enterprise, Nvidia, Shopify, and Walmart. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
